Rafarma Pharmaceuticals Inc [Wy] RAFA

$0.01 +0.00 (3.57%)

Valuation

Market cap
—
Revenue TTM
$0
Net income TTM
$0
PE ratio
—
Forward PE
—
Profit margin
0.00%
Debt to equity
—

Trading

Volume
10,261
Avg volume
22,478
Day's range
$0.01 – $0.01
Shares out
—
Stochastic %K
0%
Beta
—
Analysts
Strong Buy
Price target
—

Price

Company profile

Rafarma Pharmaceuticals, Inc., a multi-product pharmaceutical company, produces and sells drugs, generic antibiotics, and specialty pharmaceuticals in Russia. It offers cephalosporin-based products, antibiotics of non-ß structure, and anti-cancer drugs in the form of injections, ampulla packaged products, child suspensions, tablets, and capsules. The company also provides drugs for accidental wounds, inflammatory eye...

Show more

Rafarma Pharmaceuticals, Inc., a multi-product pharmaceutical company, produces and sells drugs, generic antibiotics, and specialty pharmaceuticals in Russia. It offers cephalosporin-based products, antibiotics of non-ß structure, and anti-cancer drugs in the form of injections, ampulla packaged products, child suspensions, tablets, and capsules. The company also provides drugs for accidental wounds, inflammatory eye diseases, and immunological disorders. The company has a collaboration agreement with PlantEXT Ltd. to research and manufacture the first medical cannabis suppositories for patients suffering from inflammatory bowel disease. Rafarma Pharmaceuticals, Inc. was formerly known as Johnston Acquisition Corp. and changed its name to Rafarma Pharmaceuticals, Inc. in October 2012. The company is based in Sandy, Utah with a manufacturing and distribution facility in Russia. As of October 19, 2020, Rafarma Pharmaceuticals, Inc. operates as a subsidiary of R. & D. Biocogency Laboratories Inc. Ltd.

Industry
Drug Manufacturers - Specialty & Generic
Sector
Healthcare
Phone
801-210-7135
Website
https://rafarma.si
Address
49 West 9000 South, Suite 1, Sandy, United States

Latest news

No headlines yet.